Loading...
Guest User
Welcome! Please login.
| IPO Listing At | NSE SME |
| SME IPO Issue Type | Book Build Issue |
| Total Issue Size | ₹27.52 Cr |
| Reserved for Market Maker | ₹1.38 Cr |
| Net Issue Size | ₹27.52 Cr |
| Fresh Issue | ₹26.14 Cr |
| Face Value | ₹10 Per Equity Share |
| Price Band | ₹120.00-128.00 per share |
| NSE Code | CURIS |
| Registrar | MUFG Intime India Pvt.Ltd. |
| Lead Managers | Finaax Capital Advisors Pvt.Ltd. |
| Allotment Status | |
| DRHP |
| RHP |
| Final Prospectus |
| Anchor List |
 ₹0 A/C OpeningFree MF ₹20F&O Trade ₹0Delivery 1Cr+Customers Open Free Account → |
 ₹0 A/C Opening₹0 AMC Trading Account ₹20F&O Trade ₹20Delivery FreeIPO Apply Open Free Account → |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 2,000 shares · Multiples of 1,000 shares
Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.
The company manufactures pharmaceutical products globally and domestically on a loan license or contract basis, as well as for its own brand marketing.
The company serves over 100 corporate clients on loan licenses or contract manufacturing and 2 clients for its own brand marketing in Yemen and Kenya.
Products:
The company operates a state-of-the-art manufacturing facility in Sanand, Gujarat, adhering to stringent quality control measures to ensure product safety and efficacy.
As of July 31, 2025, the company has 95 permanent employees.
Competitive Strengths:
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Capital Expenditure towards Upgradation/Improvement of the existing Manufacturing Facilities | 2.44 |
| 2 | Capital Expenditure towards Construction of a Storage Facility | 3.62 |
| 3 | Pre-payment/Repayment of outstanding Secured Loans | 1.86 |
| 4 | Product Registrations in other countries | 2.69 |
| 5 | Funding working capital requirements | 11.25 |
| 6 | General Corporate Purposes | 2.85 |
| 7 | Issue Expenses | 2.80 |
| Total | 27.52 |
| Period Ended | 31 Jul 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 56.29 | 42.53 | 33.88 | 29.75 |
| Total Income | 19.51 | 49.65 | 35.87 | 36.42 |
| Profit After Tax | 2.87 | 6.11 | 4.87 | 1.88 |
| EBITDA | 4.24 | 9.54 | 8.39 | 3.28 |
| NET Worth | 19.10 | 16.23 | 5.87 | 1.01 |
| Reserves and Surplus | 13.16 | 10.29 | 5.37 | 0.51 |
| Total Borrowing | 15.32 | 15.62 | 17.09 | 16.19 |
| Amount in ₹ Crore | ||||
| KPI | Mar 31, 2025 |
|---|---|
| ROE | 55.25% |
| ROCE | 27.83% |
| Debt / Equity | 0.96% |
| RoNW | 37.62% |
| PAT Margin | 12.43% |
| EBITDA Margin | 19.41% |
| Price to Book Value | 12.64 |
| Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 10.29 | 10.66 |
| P/E (x) | 12.44 | 12.01 |
| Promoter Holding | 92.68% | 68.03% |
| Market Cap | ₹103.48 Cr. | |
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Book Running Lead Manager fees | 0.20 |
| 2 | Fees Payable to Registrar to the Issue | 0.01 |
| 3 | Fees Payable Advertising and Printing Expenses | 0.04 |
| 4 | Fees Payable to Regulators including Stock Exchanges and other Intermediaries | 0.10 |
| 5 | Fees payable to Peer Review Auditor and Legal Advisor | 0.05 |
| 6 | Fees Payable to Market Maker (for Three Year) | 0.12 |
| 7 | Escrow Bank Fees | 0.01 |
| 8 | Others (Fees payable for marketing & distributing expenses, selling commission, brokerage, processing fees, underwriting fees and miscellaneous expenses) | 2.27 |
Last Updated on 20-Nov-2025 10:22:57
